Abstract
Psoriasis, a common skin disorder, affects over 1 percent of the population of the United States. The majority of these patients have limited disease that can be managed with topical therapy. Topical treatment includes corticosteroids, tar, anthralin and keratolytic agents. Calcipotriene, a new topical treatment for psoriasis of mild to moderate severity, is a vitamin D derivative that inhibits epidermal cell proliferation in vitro. Treatment with calcipotriene results in decreased redness, scaling and thickness of the plaque. Calcipotriene is comparable to mid-potency topical corticosteroids in efficacy, but it does not cause skin atrophy and apparently does not lead to tachyphylaxis. Irritant dermatitis is a common side effect of calcipotriene, especially when it is applied to the face. Careful patient monitoring is recommended because alterations in calcium metabolism have been reported to occur with use of calcipotriene.
| Original language | English |
|---|---|
| Pages (from-to) | 237-240 |
| Number of pages | 4 |
| Journal | American Family Physician |
| Volume | 52 |
| Issue number | 1 |
| State | Published - Jan 1 1995 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Treatment of psoriasis : Role of calcipotriene. / Kirsner, Robert; Federman, D.
In: American Family Physician, Vol. 52, No. 1, 01.01.1995, p. 237-240.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of psoriasis
T2 - Role of calcipotriene
AU - Kirsner, Robert
AU - Federman, D.
PY - 1995/1/1
Y1 - 1995/1/1
N2 - Psoriasis, a common skin disorder, affects over 1 percent of the population of the United States. The majority of these patients have limited disease that can be managed with topical therapy. Topical treatment includes corticosteroids, tar, anthralin and keratolytic agents. Calcipotriene, a new topical treatment for psoriasis of mild to moderate severity, is a vitamin D derivative that inhibits epidermal cell proliferation in vitro. Treatment with calcipotriene results in decreased redness, scaling and thickness of the plaque. Calcipotriene is comparable to mid-potency topical corticosteroids in efficacy, but it does not cause skin atrophy and apparently does not lead to tachyphylaxis. Irritant dermatitis is a common side effect of calcipotriene, especially when it is applied to the face. Careful patient monitoring is recommended because alterations in calcium metabolism have been reported to occur with use of calcipotriene.
AB - Psoriasis, a common skin disorder, affects over 1 percent of the population of the United States. The majority of these patients have limited disease that can be managed with topical therapy. Topical treatment includes corticosteroids, tar, anthralin and keratolytic agents. Calcipotriene, a new topical treatment for psoriasis of mild to moderate severity, is a vitamin D derivative that inhibits epidermal cell proliferation in vitro. Treatment with calcipotriene results in decreased redness, scaling and thickness of the plaque. Calcipotriene is comparable to mid-potency topical corticosteroids in efficacy, but it does not cause skin atrophy and apparently does not lead to tachyphylaxis. Irritant dermatitis is a common side effect of calcipotriene, especially when it is applied to the face. Careful patient monitoring is recommended because alterations in calcium metabolism have been reported to occur with use of calcipotriene.
UR - http://www.scopus.com/inward/record.url?scp=0028997113&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028997113&partnerID=8YFLogxK
M3 - Article
VL - 52
SP - 237
EP - 240
JO - American Family Physician
JF - American Family Physician
SN - 0002-838X
IS - 1
ER -